Shrika is a researcher in academia for the past 10 years, working mainly in medicinal chemistry involving cross-frontiers between chemistry and biochemistry. She has obtained a BSc degree in Chemistry, followed by a master degree also in Chemistry and ended, in 2017, a Ph.D. degree in medicinal chemistry. Her Ph.D. project was focused on finding new potential biomarkers of activation and/or of exposure of two non-nucleoside reverse transcriptase inhibitors (Nevirapine and Efavirenz). Here, she developed skills as synthetic organic chemist combined with expertise in high-resolution mass spectrometry (HRMS-QTOF- RSLC nano system). Her major research interests concern on elucidation of molecular mechanisms induced by approved therapeutic drugs, involving the synthesis and (bio)activation of drug metabolites, which were then used to modify a model protein (HSA) and human histone proteins forming covalent protein adducts. The structural analysis of these metabolites and/or drug-protein adducts were mainly supported by NMR, High Performance Liquid Chromatography and High Resolution Mass Spectrometry tool. From the PhD project work, seven papers were published in international journals referenced in ISI database (3 papers as author and 4 papers as co-author. Presently, her main research area is development and formulation of new potential molecules from a family of azaaurone-based derivatives, which have been found active active against M.tb, including multidrug- and extensively drug-resistant tuberculosis from clinical isolates, at a submicromolar level. She has been focused in SAR exploration studies and ADME profiling of newly synthesized derivatives in order to enhance their activity, metabolic stability and solubility.